A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Bevacizumab
  • Brain Neoplasms
  • Glioblastoma
  • Neoplasm Recurrence, Local
  • Piperazines
  • Quinazolines

abstract

  • Median overall and progression-free survival was 11 and 4.1 months; progression-free survival at 6 months was 23%. All patients suffered treatment-related toxicities; common grade ≥3 toxicities were hypertension (17.1%), muscle weakness (17.1%), lymphopenia (14.6%) and hypophosphatemia (9.8%). Four of six with grade ≥3 tandutinib-related myasthenic-like muscle weakness had electromyography-proven neuromuscular junction pathology. Tandutinib with bevacizumab was as effective but more toxic than bevacizumab monotherapy.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5514626

Digital Object Identifier (DOI)

  • 10.2217/cns-2015-0010

PubMed ID

  • 26860632

Additional Document Info

start page

  • 59

end page

  • 67

volume

  • 5

number

  • 2